ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / IOVA / financials
TARS (50) RLAY (39) ADPT (48) DNLI (35) ⌘ Pro Terminal β†’

Iovance Biotherapeutics Inc. (IOVA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$8.02 -5.42% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.93

Iovance Biotherapeutics Inc. (IOVA) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $3.63B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IOVA Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is IOVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $8.02 (-5.42% 1D, market cap $3.63B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, IOVA ranks #298 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does IOVA compare to TARS and RLAY in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IOVA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 34.3%, and ROIC of -35.0%. By comparison, TARS (Tarsus Pharmaceuticals Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC -24.1%, cap $3.61B) and RLAY (Relay Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.79B). Among the 5-stock peer group, IOVA leads on earnings multiple (N/A) while ADPT leads on capital efficiency (-12.5% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IOVA?
β–Ό

Per IOVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001425205), Iovance Biotherapeutics Inc. generated $263.5M in revenue (+60.6% YoY), -$391.0M in net income, and -$336.2M in free cash flow against $913.2M in total assets and $96.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.93 (-1.17%)🧬 Dilution Drag (+1.92% YoY Shares)βš™οΈ Cash Engine: 9/20 (D) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (47/100 Β· D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510047
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- Β· Rk C-
Cash (9)Whales (9)SEC (14)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$16 Bull$8 Base$6 Bear
πŸ“¬ FREE IOVA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for IOVA)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
πŸ” WHY IOVA SCORES 47/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (30% of score)

Altman Z-Score 7.08 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 4/9

β–² #2 Bullish Driver: Macro Regime Fit+10/20 pts (21% of score)

FRED Regime Γ— Technicals: 46% of 52W Range β€’ RSI-14 at 31.8 (OVERSOLD (<32))

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
55
Grade C$14.72-3.9% Next Q
Q2 (-2Q)
52
Grade C-$14.14-32.4% Next Q
Q3 (-1Q)
50
Grade C-$9.56-16.1% Next Q
Current
47
Grade D$8.02-5.9% Hist 90D Ξ±
Trajectory: C (55) β†’ D (47)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a IOVA Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While IOVA currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.43) and Max Pain ($8.42) forces dealer call-delta covering toward $16.14.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IOVAβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œIOVA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How IOVA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$263.5MGross Profit $90.3M (34.3%)Cost of Sales $173.2MOp Profit $0 (0%)OpEx (R&D/SG&A) $90.3MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $1.2M
FY24
Rev $164.1M
FY25
Rev $263.5M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$263.5M34.3%-153.1%-$391.0M-$336.2M-45%
FY 2024$164.1M43.2%-240.9%-$372.2M-$364.0M-45%
FY 2023$1.2M34.3%-38735%-$444.0M-$361.9M-25.3%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IOVA)

  • βœ“Walkthrough of IOVA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
IOVA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +101.51%β–² ASCENDING CHANNEL
2026-11-04O $8.48H $8.48L $8.02C $8.02VOL 21.05M
RES: $18.92SUP: $4.85SMA50: $11.43SMA200: $5.97
$16.25$12.60$8.94$5.29$1.64RES $18.92SUP $4.85$8.022026-05-052026-06-222026-08-062026-09-222026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IOVA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ IOVA Butterfly Map β†’ + Track IOVA β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
25.5%/yr Implied 5Y Growth

vs. +60.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IOVA today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for IOVA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IOVA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IOVA)

Health Care Rank #298 of 1015 βš”οΈ TARS vs IOVA Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (IOVA vs. TARS, RLAY, ADPT, DNLI)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Iovance Biotherapeutics Inc. (IOVA) ranks #298 by composite RQD confidence (47/100, grade D) and #186 by equity capitalization ($3.63B). Within this direct 5-issuer industry benchmark cohort, IOVA leads on earnings valuation at N/A trailing P/E, while ADPT leads on capital efficiency and profitability with -12.5% ROIC and 74.2% gross margin. TARS currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with IOVA at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IOVA ACTIVE
Iovance Biotherapeutics Inc.
D 47/100 β€” 34.3% -35.0% -5.42% $3.63B Benchmark Subject
TARS
Tarsus Pharmaceuticals Inc.
D 50/100 β€” β€” -24.1% -2.04% $3.61B /tars-vs-iova β†’
RLAY
Relay Therapeutics Inc.
D- 39/100 β€” β€” -35.0% -5.83% $3.79B /rlay-vs-iova β†’
ADPT
Adaptive Biotechnologies Corporation
D 48/100 β€” 74.2% -12.5% -5.93% $4.00B /adpt-vs-iova β†’
DNLI
Denali Therapeutics Inc.
D- 35/100 β€” β€” -35.0% -0.42% $3.01B /dnli-vs-iova β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001425205 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Iovance Biotherapeutics Inc. (IOVA) reported GAAP revenue of $263.5M (+60.6% vs. FY2024 revenue of $164.1M , and +22061.6% cumulative change since FY2023) , GAAP net income of -$391.0M, operating cash flow of -$302.4M, and free cash flow of -$336.2M (+7.6% YoY). On the balance sheet, IOVA closed FY2025 with $913.2M in total assets against $96.6M in total debt (Altman Z-Score: 7.08, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $263.5M -$391.0M -$302.4M -$336.2M $913.2M $96.6M
FY2024 (FY) 2024-12-31 $164.1M -$372.2M -$353.0M -$364.0M $910.4M $90.0M
FY2023 (FY) 2023-12-31 $1.2M -$444.0M -$361.8M -$361.9M $2.38B $557.3M

3. IOVA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IOVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $8.02 (-5.42% 1D, market cap $3.63B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, IOVA ranks #298 in composite RQD confidence.

How does IOVA compare to TARS and RLAY in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IOVA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 34.3%, and ROIC of -35.0%. By comparison, TARS (Tarsus Pharmaceuticals Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC -24.1%, cap $3.61B) and RLAY (Relay Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.79B). Among the 5-stock peer group, IOVA leads on earnings multiple (N/A) while ADPT leads on capital efficiency (-12.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IOVA?

Per IOVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001425205), Iovance Biotherapeutics Inc. generated $263.5M in revenue (+60.6% YoY), -$391.0M in net income, and -$336.2M in free cash flow against $913.2M in total assets and $96.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IOVA trading relative to its 50-day, 200-day, and 52-week technical levels?

IOVA last traded at $8.02 (-5.42% on volume of 21,047,700 shares), positioning the stock -29.83% below its 50-day simple moving average ($11.43) and +34.34% above its 200-day simple moving average ($5.97). Across its 52-week range of $1.76 to $15.37, IOVA sits at the 46.0% percentile with a 14-day RSI of 31.8 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($7.02 to $9.02).

Direct Sub-Reports: IOVA RQD Cockpit IOVA 12M Forecast IOVA Earnings & Move IOVA Dividends & DRIP IOVA Insiders & 13F IOVA Whale Options IOVA Profit Sankey IOVA News & Why
ROARABLE RATING BRIEF β€’ RQD 47/100 (D) βœ“ SEC XBRL & RQD VERIFIED

IOVA β€” Iovance Biotherapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Iovance Biotherapeutics Inc. (IOVA) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $8.02 (-5.42% 1D, market capitalization $3.63B).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 34.3%, operating margin of -60.0%, and free cash flow yield of -7.76%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (14/20): Incorporates a 0.99x equity beta, Altman Z-Score of 7.08, Piotroski F-Score of 4/9, and Debt/Equity of 0.13x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Iovance Biotherapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Reported revenue rose from $1.2M in FY 2023 to $164.1M in FY 2024 and $263.5M in FY 2025 but the source does not identify the sources of that revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Iovance Biotherapeutics Inc. (IOVA) reported $263.5M in annual revenue (up from $164.1M in FY2024, +60.6% YoY) and -$391.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.2M revenue, -$444.0M net income) through FY2025, IOVA scaled operating cash flow to -$302.4M and free cash flow to -$336.2M, backed by $913.2M in total assets against $96.6M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D β€’ RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -7.76% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $1.76 – $15.37 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 0.99x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), IOVA carries a macro regime beta of 0.99 and gross margin of 34.3%.

  • Key Question #1: Can IOVA sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $263.5M and free cash flow of -$336.2M, how will capital allocation balance growth reinvestment against $96.6M in total debt?
  • Key Question #3: How sensitive is IOVA's 33.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.99x)?

IOVA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Iovance Biotherapeutics Inc. (IOVA) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to IOVA Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IOVA Bull vs. Bear Conversation Board β€” What's Your Call at $8.02?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IOVA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IOVA:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $10.68 (+25.9%)
πŸ“Œ Pinned Debate

Balance sheet strength (Altman Z 7.08, Debt/Equity 0.13) and reported revenue growth to $263.5M in FY 2025 give the company a financial

Long IOVA at $8.48 targeting $10.68. Balance sheet strength (Altman Z 7.08, Debt/Equity 0.13) and reported revenue growth to $263.5M in FY 2025 give the company a financial base to work from.. Institutional whale score is 9/20 and the risk/reward vs. the $1.64 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader πŸ‚ BULL

@ForensicBear Shorting a 9/20 institutional whale-flow stock at $8.48 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $6.70 (-21.0%)
Spot @ $8.48

Operating losses of -$403.4M in FY 2025, ROIC of -35%, and an RQD Insider Conviction score of 5/20 point to weak fundamentals and limit

Fading this rally in IOVA at $8.48. Operating losses of -$403.4M in FY 2025, ROIC of -35%, and an RQD Insider Conviction score of 5/20 point to weak fundamentals and limited insider confidence.. With a beta of 0.99 and the stock sitting at $8.48 (52-wk range $1.64–$15.37), the easy multiple expansion is already priced in.

LIVE TAPE